Advancing mental health through scientific innovation
A global mental health crisis
One in eight people worldwide is affected by a mental health condition, according to the World Health Organization (WHO estimate). These conditions encompass a range of challenges, including depression, substance use disorder and post-traumatic stress disorder (PTSD).
At Pacalis, we believe the current state of mental healthcare is not enough. We are committed to transforming the landscape of mental health treatment and alleviating this global burden.
Our Mission
Driven by the urgent need to address the global mental health crisis, our mission is to deliver pioneering, evidence-based therapeutics that significantly improve the lives of individuals.
Our Values
Scientific Excellence
We are committed to advancing mental health through the highest standards of scientific rigor and innovation, ensuring that our discoveries translate into impactful, safe, and effective therapies.
Patient-focused Innovation. Impactful Outcomes
We are committed to ensuring that our therapies are not only accessible and effective but also grounded in rigorous scientific research, ultimately creating lasting, positive outcomes for patients worldwide.
Efficient and Ethical Drug Development
We strive for efficiency and precision in our drug development process, adhering to the highest ethical standards to bring transformative treatments to market as swiftly as possible.
Collaboration and Integrity
We believe in collaboration—across disciplines, sectors, and borders—to foster an environment where new ideas thrive and breakthrough therapies are realized.
Pacalis: Latin. Adjective.
Of or pertaining to peace, peaceful.
Pacalis Therapeutics Pty Ltd is a privately-held, neuroscience biotechnology company focused on the optimization and development of next-generation medicines for key classes of mental health disorders.
Our competitive advantage
Leveraging the combined expertise of our co-founders in pharmacology, neuroscience, and drug discovery, Pacalis is at the forefront of developing first-in-class and best-in-class therapeutics for a range of mental health conditions. Our current focus includes Major Depressive Disorder (MDD), Substance Use Disorder (SUD), and Post-Traumatic Stress Disorder (PTSD).
Pacalis is working across two programs acting via the serotonin 5-HT2A receptor. Our pipeline consists of small molecular weight compounds, all designed with the objective of developing a CNS-active drug, ideally capable of promoting neuroplasticity, with an emphasis on oral administration.
With rigorous scientific methodology and streamlined drug development, we aim to bring novel, highly effective therapies to those who need them most.
The Experienced Team Driving Pacalis
-
Warwick Tong
Director
-
David Bibby
CEO & Co-Founder
-
Chris Langmead
Chief Scientific Adviser & Co-Founder
-
Arthur Christopoulos
Co-Founder
For Investors & Strategic Partners
We’re building more than a biotech company — we’re unlocking new possibilities in medications that seek to reshape how we treat key mental health conditions. While we’re still early in our journey, we’ve laid strong scientific and commercial foundations.
We’re seeking investors who understand the long game of deep tech and share our ambition to bring breakthrough science to the real world. If you're looking to back a bold team tackling a high-impact challenge, we'd love to connect.
